MindBio Therapeutics (MBIO)

BRIEF

published on 08/19/2024 at 13:25, 4 months 2 days ago

MindBio Reports Sustained Antidepressant Response Post Microdosing Treatment

Clinical Trials Microdosing LSD MindBio Therapeutics Mental Health Treatment Antidepressant Response
PRESS RELEASE

published on 08/19/2024 at 13:20, 4 months 2 days ago

MindBio Announces Sustained Antidepressant Response 3-Months Post Treatment in Microdosing Depression Clinical Trials
MindBio reports sustained antidepressant response in depressed patients three months post MB22001 treatment. Excellent safety and efficacy shown in Phase 2A clinical trials

MindBio Phase 2A Clinical Trials Antidepressant Response MB22001 Treatment Sustained
BRIEF

published on 08/01/2024 at 11:25, 4 months 20 days ago

MindBio Therapeutics Appoints Haywood Securities for Strategic Investment Advisory

Psychedelic Medicine Strategic Investment Clinical Trials Mental Health Biopharmaceutical
PRESS RELEASE

published on 08/01/2024 at 11:20, 4 months 20 days ago

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Therapeutics appoints Haywood Securities Inc. as strategic advisor to support investment initiatives. Company progressing with Phase 2B clinical trials for psychedelic medicine MB22001

Psychedelic Medicine Clinical Trials Investment MindBio Therapeutics Haywood Securities Inc.
BRIEF

published on 07/08/2024 at 14:25, 5 months 13 days ago

MindBio Therapeutics CEO Updates Shareholders on Clinical Trials Progress

Clinical Trials Mental Health MB22001 MindBio Psychiatric Medicine
PRESS RELEASE

published on 07/08/2024 at 14:20, 5 months 13 days ago

Mindbio Therapeutics CEO Issues Letter To Shareholders
MindBio Therapeutics Corp. issues shareholder update on Phase 2B clinical trials progress, focusing on treating Major Depressive Disorder & Advanced Stage Cancer - End of Life Distress related Depression and Anxiety with MB22001 drug

MindBio Therapeutics Corp. Major Depressive Disorder Phase 2B Clinical Trials MB22001 Drug Advanced Stage Cancer
BRIEF

published on 06/20/2024 at 12:15, 6 months 1 day ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

Depression Clinical Trials MB22001 Microdosing MindBio Therapeutics
PRESS RELEASE

published on 06/20/2024 at 12:10, 6 months 1 day ago

MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials
MindBio Therapeutics reports significant and sustained reduction in depression symptoms with MB22001 microdosing trials. Phase 2B trials show promise for mental health treatment

Depression MB22001 Microdosing MindBio Therapeutics Phase 2B Trials
BRIEF

published on 06/12/2024 at 10:25, 6 months 9 days ago

MindBio Therapeutics Reports Improvement in Depression Trial Outcomes

MB22001 Microdosing MindBio Therapeutics Depression Trial Psychiatric Medicine
PRESS RELEASE

published on 06/12/2024 at 10:20, 6 months 9 days ago

MindBio Therapeutics Reports Secondary Data: Improvement of Psychological Outcomes & Safety Results in Depressed Patients from Phase 2A Depression Trial
MindBio Therapeutics Corp. reports positive secondary data from groundbreaking microdosing depression trial with MB22001, showing significant reductions in anxiety, stress, and depression

MindBio Therapeutics Corp. MB22001 Microdosing Depression Trial Psychedelic Medicines Phase 2A Depression Trial

1 2 ... 5

Published on 12/21/2024 at 01:30, 17 hours 24 minutes ago

Quantum Biopharma Announces Closing of Second Tranche
Published on 12/21/2024 at 01:30, 17 hours 24 minutes ago

iMetal Resources Closes First Tranche of Previously Announced Non-Brokered Private Placement
Published on 12/21/2024 at 00:05, 18 hours 49 minutes ago

Chloeta Awarded GSA OASIS+ IDIQ Contract for Intelligence, Federal Civilian and Defense Support Services
Published on 12/21/2024 at 00:00, 18 hours 54 minutes ago

Amarc Announces Loan Extension
Published on 12/20/2024 at 23:30, 19 hours 24 minutes ago

Boron One Announces Extension to Early Warrant Exercise Incentive Program

View all ACCESSWIRE

Published on 12/21/2024 at 00:51, 18 hours 3 minutes ago

Acquisition of PSI Transcom GmbH by CHAPTERS platform Altamount Software GmbH
Published on 12/21/2024 at 00:45, 18 hours 9 minutes ago

EQS-Adhoc: PSI sells the Mobility business unit
Published on 12/20/2024 at 19:10, 23 hours 44 minutes ago

Funding Circle Plc: POS-Transaction in Own Shares
Published on 12/20/2024 at 18:56, 23 hours 58 minutes ago

CPI PROPERTY GROUP – Progress on Key Initiatives
Published on 12/20/2024 at 18:00, 1 day ago

ARYZTA AG Announces New Board Technology Committee

View all EQS

Published on 12/21/2024 at 12:17, 6 hours 37 minutes ago

AXA announces the signing of a share purchase agreement with BNP Paribas relating to the sale of AXA IM
Published on 12/20/2024 at 18:00, 1 day ago

Capital increase through exercise of subscription rights
Published on 12/20/2024 at 17:55, 1 day ago

Disclosure of trading in own shares from 16/12/2024 to 20/12/2024
Published on 12/20/2024 at 14:00, 1 day 4 hours ago

Safran: Woodward Signs Agreement to Acquire Safran’ s Electromechanical Actuation Business based in North America
Published on 12/19/2024 at 18:30, 2 days ago

Share capital decrease by way of treasury shares cancellation

View all LES ECHOS COMFI WIRE

News